quinolone : Related Words Words similar in meaning to quinolone
- sarafloxacin«
- fluoroquinolones«
- quinoline«
- quinolones«
- premafloxacin«
- levofloxacin«
- piromidic acid«
- nalidixic acid«
- pazufloxacin«
- generation«
- oxolinic acid«
- risk«
- fda«
- dna gyrase«
- ketone«
- patient«
- irloxacin«
- drug«
- ibafloxacin«
- antibiotic class«
- garenoxacin«
- gram«
- fluoroquinolone«
- moxifloxacin«
- flosequinan«
- spectrum antibiotic«
- fleroxacin«
- qt interval«
- esafloxacin«
- ciprofloxacin«
- droxacin«
- infection«
- cetefloxacin«
- generation fluoroquinolones«
- carbostyril«
- cinoxacin«
- broad-spectrum antibiotic«
- typical drug«
- balofloxacin«
- tequin«
- avelox«
- treatment«
- adverse event«
- pipemidic acid«
- levaquin«
- trovafloxacin«
- gatifloxacin«
- uncomplicated urinary tract infection«
- effect«
- pneumonia«
- child«
- alternative treatment option«
- topoisomerase iv«
- ofloxacin«
- cipro«
- line agent«
- acute bronchitis«
- multidrug resistance«
- adverse effect«
- multidrug«
- clindamycin«
- tendonitis«
- mechanism«
- fluorine atom«
- resistance«
- cephalosporin«
- severe infection«
- seizure«
- positive bacteria«
- class«
- negative bacteria«
- clinical practice«
- interaction«
- insomnia«
- risk factor«
- rupture«
- topoisomerase iv ligase domain«
- topoisomerase ii ligase domain«
- tendon issue«
- stronger label warning«
- spectrum antibiotic drug«
- safe alternative antibiotic exists«
- ruputure«
- resistant streptococcus pneumoniae working group«
- pseudomonal infection«
- prescribing indication«
- p450-inhibitory«
- oehha prop«
- nucleasic activity«
- nuclease domain intact«
- leflox«
- intact enzyme domain«
- inhalant anthrax«
- generation fluoroquinolones act«
- fourth generation fluoroquinolones«
- excitotoxic type effect«
- cystic fibrosis infection«
- chloroquine synthesis«
- c6 fluorine atom«
- antibacterial class«
- anionic fluoroquinoline«
- american thoracic society guideline«
- acute benzodiazepine withdrawal symptom due«
- acflox woodward«
- -oxacin suffix«
- central nervous system«
- antibiotic«
- zymar -opth«
- zigat«
- zenequin«
- widespread veterinary usage«
- vetequinon«
- uroxin«
- tosacin«
- tavanic«
- systemic fluoroquinolone antibacterial drug«
- severe toxicity issue«
- saraflox«
- roquinol«
- quinoline ring system«
- quinabic«
- penetrex«
- peflacine«
- panacid«
- oxaldin«
- neggram«
- megalone«
- marbocyl«
- literature dependent«
- lexinor«
- janacin«
- intracellular quinolone concentration«
- ibaflin«
- fluoroquinolone antibacterial drug«
- fluoroquinolines«
- floxasol«
- fda safety review«
- fda pediatric drug advisory committee«
- fda adverse effect«
- enroxil«
- effect reaction«
- dolcol«
- common spontaneous report«
- benzodiazepine dependent individual«
- basic pharmacophore«
- baloxin«
- ambulatory treatment«
- advocin«
- advocid«
- acuatim«
- benefit«
- zabofloxacin«
- wintomylon«
- vigamox«
- victas«
- uroflox«
- tosufloxacin«
- tarivid«
- raxar«
- quisnon«
- pediatric prescription«
- pazucross«
- ozex«
- omniflox«
- noroxin«
- nemonoxacin«
- natural antimicrobial«
- nadoxin«
- nadixa«
- musculoskeletal event«
- musculoskeletal adverse event«
- maxaquin«
- gracevit«
- george lesher«
- generation quinolone«
- fluoroquinolones experienced adverse event severe«
- fluoroquinolone antibacterial class«
- fluoroquinoline treatment«
- dicural«
- comparator antibiotic«
- clinafloxacin«
- cinobac«
- central ring system«
- cell disease patient«
- broad spectrum cephalosporin«
- antimicrobial drug advisory committee«
- virulent clostridium strain«
- temafloxacin«
- sitafloxacin«
- rufloxacin«
- quinolone family«
- prulifloxacin«
- orbifloxacin«
- orbax«
- neurological disorder myasthenia gravis«
- lomefloxacin«
- grepafloxacin«
- fluoroquinoline administration«
- family practice notebook«
- exhibit resistance«
- difloxacin«
- delafloxacin«
- danofloxacin«
- central nervous system event«
- athlete population«
- andré bryskier md«
- community«
- nadifloxacin«
- marbofloxacin«
- genitourinary infection«
- fluoroquinolone class«
- floxin«
- enoxacin«
- cns lesion«
- cns inflammation«
- baytril«
- bacterial prostatitis«
- sarafin«
- quinolone drug«
- fluoroquinolone therapy«
- factive«
- acute upper respiratory tract infection«
- spontaneous report«
- salmonella genus«
- risk management advisory committee«
- cravit«
- c-7 position«
- antibiotic misuse«
- topoisomerase iv.«
- ongoing safety concern«
- numerous pathogen«
- nervous system effect«
- gemifloxacin«
- common tendon«
- trovan«
- sparfloxacin«
- pefloxacin«
- entry page«
- antibacterial spectrum«
- generation class«
- zagam«
- oral absorption«
- generation agent«
- antibiotic regimen«
- acute respiratory illness«
- acute bacterial exacerbation«
- development«
- resistant streptococcus pneumoniae«
- multivalent cation«
- acute bacterial sinusitis«
- gabaa receptor complex«
- study drug«
- acute sinusitis«
- hospital«
- prevention study«
- enrofloxacin«
- pregnancy«
- generation drug«
- norfloxacin«
- pasil«
- active structure«
- quinolone antibiotic«
- dual action«
- sucralfate«
- clostridium difficile infection«
- clostridium difficile colitis«
- structure activity relationship«
- acute overdose«
- topoisomerase ii«
- efflux pump«
- parenteral administration«
- oral therapy«
- antibacterial drug«
- porins«
- generic equivalent«
- class 2«
- qt prolongation«
- cycloserine«
- mycoplasma pneumoniae«
- juvenile animal«
- indication«
- gastrointestinal effect«
- urinary catheter«
- macrolide«
- antibacterial effect«
- pyrazinamide«
- dna fragmentation«
- probenecid«
- constant action«
- black box warning«
- bacterial dna«
- torsades«
- intracellular pathogen«
- legionella pneumophila«
- warning«
- marginal improvement«
- antiviral agent«
- term disability«
- american thoracic society«
- ceftriaxone«
- receptor complex«
- pyelonephritis«
- treatment guideline«
- mitochondrial dna.«
- bacterial resistance«
- current recommendation«
- resistance gene«
- macrolides«
- cyclosporine«
- antibacterial agent«
- azithromycin«
- recent meta«
- infectious disease society«
- rifampin«
- marked reduction«
- cimetidine«
- drug safety«
- streptococci«
- positive coverage«
- universal standard«
- otitis medium«
- resistant bacteria«
- line therapy«
- theophylline«
- antibacterial activity«
- musculoskeletal system«
- additional risk«
- specific population«
- healthcare research«
- bone tissue«
- doxycycline«
- distillate«
- antacid«
- cytochrome p450«
- sulfonamide«
- vancomycin«
- tetracycline«
- phenytoin«
- public citizen«
- key site«
- resistant strain«
- other drug«
- pharmacokinetics«
- exacerbation«
- pediatric patient«
- osteomyelitis«
- peripheral neuropathy«
- tendinitis«
- warfarin«
- potassium channel«
- mrsa«
- target«
- u.s. center«
- bacterial cell«
- antibiotic resistance«
- third-«
- joint meeting«
- analysis«
- cardiac arrhythmia«
- malformation«
- urinary tract infection«
- rate«
- arrhythmia«
- chronic obstructive pulmonary disease«
- damage«
- prolongation«
- hypersensitivity«
- contraindication«
- plasmid«
- people«
- oxidative stress«
- natural source«
- adverse reaction«
- wide variation«
- pharmacology«
- second-«
- restlessness«
- benzodiazepine«
- carcinogen«
- corticosteroid«
- trimester«
- treatment option«
- renal failure«
- addition«
- bronchitis«
- viral infection«
- escherichia coli«
- bacterial infection«
- kidney disease«
- convulsion«
- causation«
- penicillin«
- phase ii«
- broad spectrum«
- emergency department«
- black box«
- coworkers«
- tendon«
- fourth generation«
- product«
- outgrowth«
- condition«
- professional organization«
- u.s. food«
- safety concern«
- vomiting«
- practice«
- sickle«
- 21-member joint committee«
- 6-position«